uniQure N.V. (NASDAQ:QURE) Director Sells $30,518.40 in Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Rachelle Suzanne Jacques sold 2,112 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the sale, the director now directly owns 28,346 shares in the company, valued at approximately $409,599.70. This represents a 6.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

uniQure Stock Down 2.8%

Shares of uniQure stock traded down $0.40 during trading on Friday, hitting $13.83. 536,873 shares of the stock traded hands, compared to its average volume of 1,457,890. The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53. The stock's fifty day simple moving average is $14.51 and its 200 day simple moving average is $14.04. The firm has a market cap of $757.55 million, a P/E ratio of -3.15 and a beta of 0.08. uniQure N.V. has a 52-week low of $3.73 and a 52-week high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. On average, equities analysts predict that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on QURE shares. Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Wells Fargo & Company reduced their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a research note on Monday, May 19th. Finally, Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.82.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Twin Tree Management LP acquired a new stake in uniQure during the 4th quarter worth about $77,000. Mraz Amerine & Associates Inc. acquired a new stake in shares of uniQure during the 1st quarter worth approximately $106,000. OMERS ADMINISTRATION Corp purchased a new stake in uniQure during the first quarter worth $152,000. ADAR1 Capital Management LLC acquired a new stake in uniQure during the fourth quarter valued at $177,000. Finally, Wells Fargo & Company MN increased its holdings in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.